Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997024373 - MONOCLONAL ANTIBODY ANTAGONISTS TO HAEMOPOIETIC GROWTH FACTORS

Publication Number WO/1997/024373
Publication Date 10.07.1997
International Application No. PCT/AU1996/000840
International Filing Date 24.12.1996
Chapter 2 Demand Filed 16.07.1997
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/715 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/7153
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
7153for colony-stimulating factors [CSF]
C07K 14/7155
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
715for cytokines; for lymphokines; for interferons
7155for interleukins [IL]
C07K 16/2866
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2866against receptors for cytokines, lymphokines, interferons
C07K 2319/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
Applicants
  • MEDVET SCIENCE PTY. LIMITED [AU]/[AU] (AllExceptUS)
  • LOPEZ, Angel, F. [AU]/[AU] (UsOnly)
Inventors
  • LOPEZ, Angel, F.
Agents
  • A.P.T. PATENT & TRADE MARK ATTORNEYS
Priority Data
PN 736829.12.1995AU
PN 741804.01.1996AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MONOCLONAL ANTIBODY ANTAGONISTS TO HAEMOPOIETIC GROWTH FACTORS
(FR) ANTAGONISTES D'ANTICORPS MONOCLONAUX DIRIGES CONTRE DES FACTEURS DE CROISSANCE HEMATOPOIETIQUES
Abstract
(EN)
Anti IL-3 Receptor alpha chain monoclonal antibody (MoAb) is the product of a hybridoma cell line designated 7G3. The MoAb acts as an antagonist to IL-3 in vitro activity. The MoAb binds to the N terminal domain of the IL-3 receptor alpha chain and does so competitively with IL-3 which indicates that this is, at least in part, involved in IL-3 binding. Treatment with the MoAb of fragment thereof whether recombinant or otherwise may be suitable for treating the following conditions, myeloid leukaemias, lymphomas such as follicular B cell lymphomas, or the alleviation of allergies.
(FR)
Cette invention concerne un anticorps monoclonal (MoAb) dirigé contre la chaîne alpha du récepteur d'IL-3, lequel anticorps est le produit d'une lignée de cellules hybridomes appelée 7G3. Cet MoAb agit en qualité d'antagoniste de l'activité de l'IL-3 in vitro. Le MoAb se lie à la région de l'extrémité N-terminale de la chaîne alpha du récepteur de IL-3 et le fait en compétition avec l'IL-3, ce qui indique une participation, en partie du moins, à la liaison de l'Il-3. Les traitements effectués à l'aide du MoAb ou de l'un de ses fragments, recombinés ou autres, peuvent être utilisés dans des cas tels que la leucémie myéloïde, les lymphomes tels que les lymphomes B folliculaires, ou encore pour le soulagement d'allergies.
Also published as
Latest bibliographic data on file with the International Bureau